Association of CD40 -1C/T Polymorphism in the 5′-Untranslated region with chronic HBV infection

Cellular Physiology and Biochemistry

Volumn 35, Issue 1, 2015, Pages 83-91

  Zhou, Cheng ^a   Jin, Xiaoli ^a   Tang, Jie ^a   Fei, Jiaqian ^a   Gu, Chunxia ^a   Chen, Xi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Asymptomatic HBV carriers; CD40 expression; CD40 1C T polymorphism; Immune tolerance; Soluble CD40

Indexed keywords

CD40 ANTIGEN; 5' UNTRANSLATED REGION;

5' UNTRANSLATED REGION; ADULT; ARTICLE; ASYMPTOMATIC DISEASE; B LYMPHOCYTE; CELL LEVEL; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELISA KIT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INFECTION SENSITIVITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

HEPATITIS B VIRUS;

5' UNTRANSLATED REGIONS; ADULT; ALLELES; ANTIGENS, CD40; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84920854583     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369677     Document Type: Article

References (39)

1. Trepo C, Chan HL, Lok A: Hepatitis B virus infection. Lancet DOI: 10.1016/S0140-6736(14)60220-8.
2. Chang ML, Liaw YF: Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course and management. J Hepatol. DOI: 10.1016/j.jhep.2014.08.033.
3. Amarapurkar D: Asymptomatic HBsAg carrier: A Case for Concern; in Banerjee AK, Bandyapadhyay S (eds): Med Update, Mumbai, Assoc Physici India, 2011, vol 21, pp 358-363.
4. Knolle PA, Thimme R: Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 2014;146: 193-1207.
5. Zeng Z: Human genes involved in hepatitis B virus infection. World J Gastroenterol 2014;20:7696-7706.
6. Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greer S, Witt MD, Goedert JJ, Hilgartner M, Majeske A, O'Brien SJ, Thomas DL, Carrington M: Genetic protection against hepatitis B virus conferred by CCR5 Delta32: Evidence that CCR5 contributes to viral persistence. J Virol 2007;81:441-445.
7. Deng G, Zhou G, Zhang R, Zhai Y, Zhao W, Yan Z, Deng C, Yuan X, Xu B, Dong X, Zhang X, Zhang X, Yao Z, Shen Y, Qiang B, Wang Y, He F: Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008;134:716-726.
8. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/ CD40L engagement in the immune system. Immunol rev 2009;229:152-172.
9. Zhang K, Zhang L, Zhu D, Bae D, Nel A, Saxon A. CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE. J Allergy Clin Immunol 2002;110:421-428.
10. Danese S, Sans M, Fiocchi C: The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004;53:1035-1043.
11. Merrill JT: Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 2013; 148: 369-375.
12. Pilat N, Schwarz C, Wekerle T: Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation. Curr Opin Organ Transplant.2012;17:368-375.
13. Tang Y, Chen Y, Ni B, Yang D, Guo S, Wu Y: Up-regulation of the expression of costimulatory molecule CD40 in hepatocytes by hepatitis B virus x antigen. Biochem Bioph Res Co 2009;384:12-17.
14. Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U: Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999;154:1711-1720.
15. Shiraki K, Sugimoto K, Okano H, Wagayama H, Fujikawa K, Yamanaka T, Ito T, Ohmori S, Sakai T, Takase K, Nakano T: CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med 2006;18:559-563.
16. Yan J, Jie Z, Hou L, Wanderley JL, Soong L, Gupta S, Qiu S, Chan T, Sun J: Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice. Hepatology 2011;53:1455-1467.
17. Zhou F, Ajuebor MN, Beck PL, Le T, Hogaboam CM, Swain MG: CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology 2005;42:372-380.
18. Rau SJ, Hildt E, Himmelsbach K, Thimme R, Wakita T, Blum HE, Fischer R: CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway. Hepatology 2013;57:23-36.
19. Schmilovitz-Weiss H, Belinki A, Pappo O, Sulkes J, Melzer E, Kaganovski E,Kfir B, Tur-Kaspa R, Klein T, Ben- Ari Z: Role of circulating soluble CD40 as an apoptotic marker in liver disease. Apoptosis 2004;9:205-210.
20. Shen HH, Sun HY, Zhao JM, Hou J, Bai BK, Hu Y, Kong W, Mao PY: Level and clinical significance of soluble CD40 in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008;22:373-375. Chinese
21. Liu H, Qi CJ, Zhuang YM, Gan JH, Li HL, Yin CS, Zhang XG: Serum levels and clinical significance of soluble CD40 in liver disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006;22:738-741. Chinese.
22. Kozak M: Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 2005;361:13-37.
23. Inoue N, Watanabe M, Yamada H, Takemura K, Hayashi F, Yamakawa N, Akahane M,Shimizuishi Y, Hidaka Y, Iwatani Y: Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4,PTPN22, CD40, FCRL3 and ZFAT, previously revealed in genome-wide association studies. J Clin Immunol 2012;32:1243-1252.
24. Sokolova EA, Malkova NA, Korobko DS, Rozhdestvenskii AS, Kakulya AV, Khanokh EV, Delov RA, Platonov FA, Popova TY, Aref' eva EG, Zagorskaya NN, Alifirova VM, Titova MA, Smagina IV, El' chaninova SA, Popovtseva AV, Puzyrev VP, Kulakova OG, Tsareva EY, Favorova OO, Shchur SG, Lashch NY, Popova NF, Popova EV, Gusev EI,Boyko AN, Aulchenko YS, Filipenko ML: Association of SNPs of CD40 gene with multiple sclerosis in Russians. PLoS One 2013;8:e61032.
25. Wang M, Li Y, Li W, Xia ZE, Wu Q: The CD40 gene polymorphism rs1883832 is associated with risk of acute coronary syndrome in a Chinese case-control study. DNA Cell Biol 2011;30:173-178.
26. Yan J, Wang C, Du R, Liu P, Chen G: Association analysis of CD40 gene polymorphism with acute coronary syndrome. Clin Exp Med 2010;10:253-258.
27. Chen YM, Yu CP, Wan SY, Shen YJ, Lin DY: Impact of gender, viral transmission and aging in the prevalence of hepatitis B surface antigen. Chang Gung Med J 2009;32:155-164.
28. Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R, Bo S: Gender specific medicine in liver diseases: a point of view. World J Gastroenterol. 2014;20:2127-2135.
29. Esposito P, Rampino T, Gregorini M, Gabanti E, Bianzina S, Dal Canton A: Mechanisms underlying sCD40 production in hemodialysis patients. Cell Immunol. 2012;278:10-15.
30. Bourgeois C, Rocha B, Tanchot C: A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002;297:2060-2063.
31. Bachmann MF, Hunziker L, Zinkernagel RM, Storni T, Kopf M: Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur J Immunol 2004;34:317-326.
32. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV: CD40 activation rescues antiviral CD8 T cells from PD- 1-mediated exhaustion. PLOS Pathog 2013;9:e1003490.
33. Jacobson EM, Concepcion E, Oashi T, Tomer Y: A Graves disease-associated Kozak sequence singlenucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005;146:2684-2691.
34. Esposito P, Rampino T, Dal Canton A: Soluble CD40 as a modulator of CD40 pathway. Immunol Lett 2012;147:85-86.
35. Tone M, Tone Y, Fairchild PJ, Wykes P, Waldmann H: Regulation of CD40 function by its isoforms generated through alternative splicing, Proc Natl Acad Sci USA 2001;98:1751-1756.
36. Eshel D, Toporik A, Efrati T, Nakav S, Chen A, Douvdevani A: Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing, Mol Immunol 2008;46:250-257.
37. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dchanet-Merville J: Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 2003;278:32801-32809.
38. Lapiński TW, Pogorzelska J, Grzeszczuk A, Swiderska M, Kowalczuk O, Nikliński J, Flisiak R: The importance of sCD40 and sCD40L concentration in patients with chronic HCV infection and HIV co-infection. Przegl Epidemiol 2014;68:11-15, 105-108.
39. Zhang B, Wu T, Song C, Chen M, Li H, Guo R: Association of CD40-1C/T polymorphism with cerebral infarction susceptibility and its effect on sCD40L in Chinese population. Int Immunopharmacol 2013;16:461-465.